



File available for download on our website

LISAvienna Highlights

Fall & Winter 2022

HOOKIPA Pharma: Strategic collaboration license agreement with Roche
page 7

LIVIN farms and XUND from Vienna closed series A rounds to expand operations
page 8

Life Sciences competition 2022: Celebrating the winners

The five best life sciences concepts from a pool of 46 participants at the tenth **aws BoB – Best of Biotech** start-up competition were honored by the Austrian Federal Ministry of Labour and Economy at a festive awards ceremony at Palais Ferstel in Vienna.



Foto © aws / Fehringner

The winners are Velaex Technologies, Ludwig Med, NovoArc, RevlVe and rotable. Congratulations and keep up the good work! It was a great pleasure for LISAvienna to award the next “Golden Viennese Hearts” to the best submissions in the medtech

category. Boehringer Ingelheim and Takeda were on board as sponsors, too.

See page 3 for further details.

www.bestofbiotech.at



© LISAvienna / Beranek

Dear readers!

The last few months have been very special for LISAvienna. We celebrated our 20th birthday, welcomed Elvira Kainersdorfer as our new team member, and our Regulatory Conference on Medical Devices and IVD attracted hundreds of participants. In addition, we received a lot of interesting news from companies and research institutions in Vienna - but see for yourself. And please go to our website for a more comprehensive overview.

When preparing for our celebration of LISAvienna's anniversary and Vienna's flourishing life sciences sector at the Vienna City Hall we dug in our photo archive and found a lot of great memories. Some of them have been included in a short clip that was presented during our welcome address. We also created a slide show for you from the photos of the event. We recommend watching these two videos on our YouTube channel. You will also find clips there that allow you to get to know a few key players in Vienna's dynamic life sciences community.

We invite you to subscribe to our newsletter online and to follow us on LinkedIn and Twitter to stay up to date. We are looking forward to meeting you at the upcoming events or receiving your requests for personalized advice free of charge.

Johannes Sarx and Philipp Hainzl
LISAvienna Executive Board

+++ Trade shows and conferences +++

Arab Health

Dubai, 30.1.-2.2.2023

BIO-Europe Spring

Basel, 20.-22.3.2023

HIMSS

Chicago, 17.-21.4.2023

DMEA

Berlin, 25.-27.4.2023

dHealth

Vienna, 16.-17.5.2023

A MEMBER OF **LISA** LIFE SCIENCE AUSTRIA



© LISAvienna / Beranek

Elvira Kainersdorfer joined the LISAvienna team as a technology expert for biotech and pharma in October. She brings with her many years of experience as a life sciences investment manager at Austria Wirtschaftsservice, and is familiar with

the Austrian start-up landscape and funding opportunities. Her comprehensive expertise in technologies, business models and market prospects and her great network in the private equity sector will bring new, positive impulses for the development of the life sciences location Vienna.

Contact

ARGE LISAvienna

Life Science Austria Vienna
Walcherstrasse 11A
1020 Vienna, Austria

PHONE: + 43 (0) 1 50175 358

E-MAIL: office@LISAvienna.at

WEB: www.LISAvienna.at

It was a blast: LISAvienna's anniversary celebration



We thank you for celebrating our 20th anniversary with us - online and offline. It was just great! Let's continue to jointly shape the future of Vienna and Austria as a prime life sciences location in the heart of Europe!



© LISAvienna / Ludwig Schedl

Continuation from page 1:

Winner Early Track Category Biotech/Pharma:

Martin Wilkovitsch - **Velaex Technologies** is working on a technology that makes it possible to release active substances directly in diseased tissue. This reduces the severe side effects of drugs.

Winner Early Track Category Medtech:

Rafael Boog - **Ludwig Med** focuses on a technology that generates music in real time and is tailored to people's data to enable clinically useful resonance effects, for example in intensive care units.

Winner Start-up Track Category Biotech/Pharma:

NovoArc - The company is developing a technol-

ogy to replace syringes with tablets. An innovative biological shell protects active ingredients and improves absorption into the body.

Winner Start-up Track Category Medtech:

RevIve - The company focuses on a pump solution for safe, cost-effective and hospital-independent treatment with intravenously administered antibiotics.

Winner Special Award Digital Health:

rotable - The company's software minimizes the time spent on administrative tasks at healthcare facilities by automating clinical rotation schedules.

Bulletin Board

Holloid won the Rudolf Sallinger Fonds S&B Award 2022

The company focuses on in-line process monitoring using artificial intelligence and digital holographic microscopy



© Fabian Gaspert

QUANTRO Therapeutics

Collaboration with Boehringer Ingelheim to develop drug candidates interfering with transcriptional regulators

www.quantro-tx.com

Max on the wall!

New "WienerWissen" street art by Käthe Schoenle and Sebastian Schager on the facade of the Max Perutz Labs Vienna



© Max Kropitz

I ♥ Vienna



© ÖGMBT 2022

Life Science Awards 2022

ÖGMBT: Life Science PhD Awards Austria go to Martin Wilkovitsch (TU Wien) and Maximilian Schneider (IMBA), and the Life Science Research Awards Austria 2022 go to Pia Gattinger (MedUni Vienna), Peter Peneder (CCRI) and Bernardo Almeida (IMP)

We had a fantastic time at BIO-Europe in Leipzig

The LISA – Life Science Austria booth attracted a large number of visitors again. It was great to finally meet friends from the international biotech community again and make new contacts. More than 50 companies from across Austria were represented at the partnering conference, of which 38 were at our booth. The regional showcase „Austria – Where innovation moves mountains!“ by ABA – Invest in Austria, with speakers from Austria Wirtschaftsservice, Boehringer Ingelheim and Biotech Austria, provided an overview on facts and figures and biotech highlights.



© EBD Group / Ludwig Schedl

FH Campus Wien

Applied Life Sciences Department and Study Programs united at Campus Favoritenstraße

© FH Campus Wien / Scheidl



F2G announces \$70 million financing

The investment will advance the development and commercialization of a new antifungal agent

www.f2g.com

WWTF granted €3.95 million

8 top class public health research projects to start in Vienna

www.wwtf.at

HeartBeat.bio

Collaboration with Boehringer Ingelheim to investigate cardiac organoids for the development of new treatments for people with heart diseases

www.heartbeat.bio



© MedUni Wien - Josephinum / Bene Croy

Reopening of the MedUni Vienna's Josephinum after four years of renovations

AUSTRIAN LIFE SCIENCES DIRECTORY



www.lifesciencesdirectory.at

UpNano: High-resolution 3D-Printing

Fresh capital to boost innovation and serial production

© UpNano GmbH



© AOP Health / Krisztian Juhasz

AOP Health celebrated 25 successful years of developing therapies for patients with rare diseases and in critical care. While the company initially had a focus on Austria and soon Europe, it is now providing its products to patients worldwide.



© aws / Anna Rauchenberger

PHÖNIX Awards 2022

Best Female Entrepreneur: Karin Fleck, Vienna Textile Lab: Colors made from naturally occurring microorganisms

Best Prototype: TU Graz, project "ElectoPower": Resource-efficient production and use of fuel cells

Best Spin-off: TU Wien spin-off company UpNano: High-resolution and fast 3D printing

Best Start-up: Myllia Biotechnology: Single-cell CRISPR screens enabling drug discovery

Saddle up for
Vienna UP'23
Let's talk startups. **Save the date!**

30.5. – 7.6. 2023

Full house at the LISAvienna Regulatory Conference on Medical Devices and In-vitro Diagnostics

More than 300 interested parties from the DACH region met in Vienna for an exchange on MDR, IVDR and FDA requirements. An expert panel discussed the advantages and challenges that entrepreneurs and regulatory experts are facing in the EU and the US. Participants were able to choose from ten seminars covering a broad range of topics.



In collaboration with en.co.tec and supported by LISA – Life Science Austria, LISAvienna organized the sixth Regulatory Conference for the life sciences community. Johannes Sarx and Philipp Hainzl, Managing Directors of LISAvienna, stated: “The legal requirements for market entry must already be considered in the early development phases for medical devices and in vitro diagnostics. To this end, we are strengthening the knowledge base and networking the key stakeholders with each other. It was especially important for us to see many new companies among the participants.”

Sharing expertise is key

Notified Bodies including mdc, TÜV Süd and SIQ, experts from AGES / BASG, the Austrian National Public Health Institute Gesundheit Österreich, business associations from Austria and Germany, consultants and successful companies all helped to make the conference a crowd magnet once again. Start-ups, SMEs and large businesses sent representatives to exchange information about

the latest developments around MDR and IVDR. International market approval in the US, UK and Switzerland was also discussed. Participants particularly valued the insights from Notified Bodies and from companies that have already successfully gone through the required processes.

Safety guarantor or innovation barrier?

A panel discussion on MDR and IVDR versus FDA shed light on opportunities and challenges characterizing regulatory affairs in the EU as compared to the US. The panelists agreed that safety requirements are justified but that there is a need to readjust details at EU’s MDR and IVDR in order to secure availability of existing and safe medical devices and IVD in the EU. Panelists expect that MDR and IVDR deadlines will be pushed back again. However, this will not be sufficient to achieve the goals that need to be met. Grandfathering, more flexible processes, and establishing a system integrator in the EU might be considered to reduce the burden on the Notified Bodies as capacities cannot meet demand and to provide legal security.


Slide decks and a photo gallery are available online at www.LISAvienna.at



HOOKIPA Pharma: Strategic collaboration and license agreement with Roche

HOOKIPA Pharma, a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced a strategic collaboration and license agreement with Roche to develop HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy.

Through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. Upon the completion of the Phase 1b trial, Roche has the right to assume development responsibility and to commercialize licensed products across multiple indications upon approval. The agreement also includes an option for Roche to license a second arenaviral cancer immunotherapy. “Roche is an ideal partner, both in terms of development and reaching patients with novel cancer therapeutics. We look forward to working with them to benefit people with KRAS-mutated cancers,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “This collaboration validates the potential of our arenavirus platform and accelerates the development pathway to bring new treatments to people with cancer.”



\$930 million milestone payments

Under the terms of the agreement, HOOKIPA has received an upfront payment of \$25 million. Roche has the option to expand the initial collaboration by adding an additional product candidate, whereafter HOOKIPA would receive an additional \$15 million payment at option exercise. Including this option payment, HOOKIPA is eligible for research, development and commercialization milestone-based payments for HB-700 and the additional product candidate totaling up to approximately \$930 million. Upon commercialization, HOOKIPA is eligible to receive tiered royalties of a high single-digit to mid-teens percentage on the worldwide net sales of HB-700 and the additional product candidate.

Advancing pipeline and job opportunities in Vienna

HOOKIPA was founded in Vienna and its stock is listed on NASDAQ: HOOK. The company operates its R&D laboratories, manufacturing and other activities at the Vienna BioCenter where it employs more than 120 people. HOOKIPA has announced plans for further growth in Vienna and is looking to attract enthusiastic and talented individuals to complement its expanding team.

www.hookipapharma.com

Why Vienna?

The Viennese biotech arena is an important and competitive hub at the center of Europe’s biotech and life science sector. It provides a highly dynamic environment on an international scale which enhances the industry’s capacity to innovate. For HOOKIPA, it provides fertile ground for advancing and delivering results that demonstrate the potential and uniqueness of our novel technology platform. Moreover, our people just love Vienna as a place to live.



© HOOKIPA Pharma

Joern Aldag, CEO, HOOKIPA Pharma

XUND closed a €6 million seed funding round to expand operations outside the DACH region

XUND provides an AI-powered health assistant designed to improve the quality and accessibility of healthcare. The API is the only one certified as a medical device (class IIa) in this field. The seed funding round was co-led by MMC Ventures and MassMutual Ventures, which were joined by RoX Health, and LANA Ventures.



Founded in 2018, XUND's goal is to revolutionize tomorrow's healthcare by delivering evidence-based solutions to patients and healthcare professionals to help them prevent, manage, and treat diseases. XUND can automatically analyze and process millions of medical publications to create the baseline for comparing it with symptoms, personal risk factors, and demographic data of individual patients to identify statistically and medically relevant causes for discomfort. XUND has already gained the trust of several prestigious clients, including Wiener Städtische Versicherung (Vienna Insurance Group) and Generali. XUND will use the new funds to push growth and advance its expansion into new markets across Europe and into the US, with entry preparations already underway with a submission to the FDA. The new funding will also allow XUND to include new product features along the patient journey and set up additional promising use cases.

www.xund.ai

LIVIN farms raised a €6 million in series A financing round led by venture investor Peter Luerssen

The industrial technology provider in the alternative protein industry enables the transformation of food waste into valuable protein. The company has developed a unique, highly scalable, and modular system to upcycle organic waste and by-products into valuable proteins, fats, and fertilizers.

The LIVIN farms insect factories are an important step towards a circular economy, where technology enables resource efficient and scalable production processes. "With our proprietary technology and biological know-how, our customers turn substantial losses on organic waste into highly attractive, additional income. At the same time, our customers contribute massively to fixing the broken food system and therefore saving the planet", says Katharina Unger, founder, and CEO of LIVIN farms. This series A investment will fuel further growth of the company and will be used for expanding the LIVIN farms team, standardization of the technical solutions and driving the initial scale-up phase.

www.livinfarms.com



Why Vienna?

"Vienna is geographically well connected with Europe and Asia, which makes it easier for our customers to visit our facility. Vienna has been voted the best city to live in and is for sure the

best city to work in, with a great transportation system and infrastructure."

Katharina Unger, CEO LIVIN farms